Vera Therapeutics Inc Cl A (VERA)

$21.76 -0.78 (-3.46%)
Market Cap 1.36B
Revenue (ttm) 0.00
Net Income (ttm) -152.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 1,018,901
Avg Vol 1,367,298
Day's Range N/A - N/A
Shares Out 63.82M
Stochastic %K 54%
Beta 1.17
Analysts Strong Sell
Price Target $64.08

Company Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A n...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 770 0077
Website: veratx.com
Address:
2000 Sierra Point Parkway, Suite 1200, Brisbane, United States
DCRMIA
DCRMIA Aug. 27 at 11:19 AM
$VERA
0 · Reply
DCRMIA
DCRMIA Aug. 26 at 3:08 PM
$VERA Vera Therapeutics stands poised for a significant upside driven by clinical, regulatory, financial, and technical developments. Extremely bullish
0 · Reply
Bigeyes2
Bigeyes2 Aug. 24 at 7:37 PM
$VERA cup and handle
0 · Reply
Arcides
Arcides Aug. 21 at 9:23 PM
$VERA this bio has made a good bounce after earnings shakeout and is consolidating good.
0 · Reply
WSRX
WSRX Aug. 18 at 8:02 PM
$VERA opened position today, 2,500 shares
0 · Reply
WSRX
WSRX Aug. 17 at 2:24 AM
$VERA super undervalued down here imo
1 · Reply
Pharaon_Cr
Pharaon_Cr Aug. 14 at 3:03 PM
$ENLV the only one going up today, clinical trials are going well !! ✅ Other Biotech seems bearish with huge price increase over the next weeks like $VERA $ATNF $TNXP $BTAI … lot of people are tacking profits before FDA results… 🐻
0 · Reply
ImTheDudeMan
ImTheDudeMan Aug. 8 at 6:09 AM
$VERA The quiet ones all deliver. See inside buys last month.
0 · Reply
JarvisFlow
JarvisFlow Aug. 7 at 9:30 PM
JP Morgan has updated their rating for Vera Therapeutics ( $VERA ) to Overweight with a price target of 53.
0 · Reply
dcrown
dcrown Aug. 6 at 5:43 PM
$VERA M & A 2025
1 · Reply
Latest News on VERA
Vera Therapeutics to Participate at Upcoming Investor Conferences

Aug 26, 2025, 4:05 PM EDT - 23 hours ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 8, 2025, 4:05 PM EDT - 18 days ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 7:00 AM EDT - 22 days ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 7:05 PM EDT - 6 weeks ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 2 months ago

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Jun 3, 2025, 6:30 AM EDT - 3 months ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Jun 2, 2025, 9:01 AM EDT - 3 months ago

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Jun 2, 2025, 8:45 AM EDT - 3 months ago

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Jun 2, 2025, 6:30 AM EDT - 3 months ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug

May 15, 2025, 2:46 PM EDT - 3 months ago

Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 6, 2025, 8:00 AM EDT - 4 months ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Apr 3, 2025, 8:00 AM EDT - 5 months ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 6 months ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:25 AM EST - 6 months ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Top 3 Health Care Stocks That Could Blast Off This Quarter

Jan 22, 2025, 6:46 AM EST - 7 months ago

Top 3 Health Care Stocks That Could Blast Off This Quarter

RDNT VKTX

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 8 months ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Oct 29, 2024, 8:21 PM EDT - 10 months ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Oct 28, 2024, 5:37 PM EDT - 10 months ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Oct 28, 2024, 10:33 AM EDT - 10 months ago

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Oct 26, 2024, 7:30 PM EDT - 10 months ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 4, 2024, 1:45 PM EDT - 11 months ago

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Oct 2, 2024, 6:30 AM EDT - 11 months ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Oct 2, 2024, 6:30 AM EDT - 11 months ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

Sep 3, 2024, 7:49 AM EDT - 1 year ago

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

ADBE CZR KYTX

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Jul 22, 2024, 8:52 AM EDT - 1 year ago

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Jun 11, 2024, 4:01 PM EDT - 1 year ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 25, 2024, 9:40 AM EDT - 1 year ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 20, 2024, 7:30 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Feb 28, 2024, 4:20 PM EST - 1 year ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 2, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Feb 1, 2024, 4:05 PM EST - 1 year ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Jan 29, 2024, 11:50 PM EST - 1 year ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Jan 25, 2024, 6:30 AM EST - 1 year ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Jan 8, 2024, 8:01 AM EST - 1 year ago

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 27, 2023, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 9, 2023, 8:00 AM EST - 1 year ago

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Nov 4, 2023, 10:00 AM EDT - 1 year ago

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Vera Therapeutics Scheduled to Present at November Investor Conferences

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Vera Therapeutics Scheduled to Present at November Investor Conferences

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Oct 13, 2023, 10:22 AM EDT - 2 years ago

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Vera Therapeutics' Promising Atacicept Drug Targets IgAN

Aug 17, 2023, 5:47 PM EDT - 2 years ago

Vera Therapeutics' Promising Atacicept Drug Targets IgAN

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target

Jul 4, 2023, 9:42 AM EDT - 2 years ago

Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target

Vera: Repurposed Molecule Program Does Not Impress

Jul 3, 2023, 1:39 PM EDT - 2 years ago

Vera: Repurposed Molecule Program Does Not Impress

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

Jun 17, 2023, 10:10 AM EDT - 2 years ago

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN

Jun 15, 2023, 4:44 PM EDT - 2 years ago

Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN

Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say

Jun 12, 2023, 3:40 PM EDT - 2 years ago

Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say

NVS TVTX

DCRMIA
DCRMIA Aug. 27 at 11:19 AM
$VERA
0 · Reply
DCRMIA
DCRMIA Aug. 26 at 3:08 PM
$VERA Vera Therapeutics stands poised for a significant upside driven by clinical, regulatory, financial, and technical developments. Extremely bullish
0 · Reply
Bigeyes2
Bigeyes2 Aug. 24 at 7:37 PM
$VERA cup and handle
0 · Reply
Arcides
Arcides Aug. 21 at 9:23 PM
$VERA this bio has made a good bounce after earnings shakeout and is consolidating good.
0 · Reply
WSRX
WSRX Aug. 18 at 8:02 PM
$VERA opened position today, 2,500 shares
0 · Reply
WSRX
WSRX Aug. 17 at 2:24 AM
$VERA super undervalued down here imo
1 · Reply
Pharaon_Cr
Pharaon_Cr Aug. 14 at 3:03 PM
$ENLV the only one going up today, clinical trials are going well !! ✅ Other Biotech seems bearish with huge price increase over the next weeks like $VERA $ATNF $TNXP $BTAI … lot of people are tacking profits before FDA results… 🐻
0 · Reply
ImTheDudeMan
ImTheDudeMan Aug. 8 at 6:09 AM
$VERA The quiet ones all deliver. See inside buys last month.
0 · Reply
JarvisFlow
JarvisFlow Aug. 7 at 9:30 PM
JP Morgan has updated their rating for Vera Therapeutics ( $VERA ) to Overweight with a price target of 53.
0 · Reply
dcrown
dcrown Aug. 6 at 5:43 PM
$VERA M & A 2025
1 · Reply
Peterson28
Peterson28 Aug. 5 at 2:16 AM
$VERA Closed the gap created on 2 June. Time to fly.
0 · Reply
Rally107
Rally107 Aug. 4 at 1:39 PM
$VERA this stock has just been getting hammered day in and day out
0 · Reply
JarvisFlow
JarvisFlow Aug. 4 at 11:30 AM
Wolfe Research updates rating for Vera Therapeutics ( $VERA ) to Peer Perform.
0 · Reply
Ron_Burn
Ron_Burn Aug. 2 at 2:50 AM
$VERA triple bottom??
0 · Reply
Arcides
Arcides Jul. 29 at 10:26 PM
$VERA pure downtrend again, all moving averages point down.
0 · Reply
Jahway
Jahway Jul. 25 at 8:21 PM
$VERA What a weird stock
1 · Reply
Peterson28
Peterson28 Jul. 23 at 5:07 PM
$VERA Wow, very narrow trading range. Why manipulating?
0 · Reply
Jahway
Jahway Jul. 23 at 12:53 AM
$VERA
0 · Reply
garbageshort
garbageshort Jul. 22 at 6:36 PM
$VERA free fall in teens
0 · Reply
garbageshort
garbageshort Jul. 22 at 12:39 PM
$VERA slow bleeding ...till Oct and then drop after Otsuka's approval
0 · Reply
Jahway
Jahway Jul. 21 at 2:52 PM
$VERA 😔👉 cmon do something
0 · Reply
Peterson28
Peterson28 Jul. 21 at 5:20 AM
$VERA This will get bought out within a month. 75 BO price.
1 · Reply